fda-approval-prediction
(2)
Intelligencia AI
Intelligencia AI is a New York-based artificial intelligence company that helps pharmaceutical and biotech organizations predict the probability of technical and regulatory success (PTRS) for drug candidates. Its patented SaaS platform harmonizes more than 1.5 billion clinical and biological data points to score how likely a drug is to advance through clinical phases and win regulatory approval, with reported prospective accuracy above 80%. The company gives R&D, business development, and portfolio teams transparent, explainable AI to de-risk investment decisions in drug development.
Dimitrios Skaltsas
Dimitrios Skaltsas is the co-founder and CEO of Intelligencia AI, a New York enterprise software company that uses machine learning and curated biomedical data to estimate the probability that a drug candidate will win regulatory approval. Trained as a lawyer in Athens and London, he spent more than a decade at McKinsey, where he built and led New Ventures' big-data and AI work for pharmaceutical R&D before co-founding Intelligencia with Vangelis Vergetis in 2017. Under his leadership the company raised a Series A, was named one of Forbes's Top AI Companies to Watch, secured a U.S. patent for its probability-of-success assessments, and landed on the Inc. 5000. He is also an Executive in Residence at INSEAD.